Equillium, Inc.

NASDAQ:EQ

Biotechnology

Healthcare
$1.10 +1.51%

+$0.05 today

Market cap
$90.56M
Beta
1.76
P/E (TTM)
-15.3
EPS (TTM)
-$0.20
52W Low $0.27High $3.45

Volume 0.89M

Average 0.60M

EQ Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Equillium, Inc.NASDAQ: EQ

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses grows, but more slowly than its trailing trend

Q1 FY2026 other income / expenses of $299K rose 38.4% year over year, behind the +83.1% change in trailing-twelve-month other income / expenses. Sequentially, it rose 59.9% from the prior quarter.

Context

  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +38.4% toward the trailing-twelve-month pace of +83.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$299K+59.9% QoQ
Last fiscal yearDec 2025
$1.24M+119.5% YoY
LTMMar 2026
$1.32M+83.1% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.4%——
1 year+119.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
1.24M USD
Year-over-year change
+119.5%

Other Income / Expenses vs competitors

How EQ compares with its peers on the latest reported figures

  • EQ's LTM Mar 2026 other income / expenses of $1.32M is the 3rd highest of the 10 companies compared; the peer median is $24.01K.
  • Its year-over-year change of +83.1% is the 4th highest of 10, against a peer median of -12.1%.
EQ Competitors Peer median
Other Income / Expenses for EQ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$189.09M +2976.4%—285.8%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$9.09M -27.2%+21.7%—
EQEquillium, Inc.LTM Mar 2026$1.32M +83.1%——
CUECue Biopharma, Inc.LTM Mar 2026$561K +2.7%+24.9%1.7%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$168.08K +200.4%+10329392.1%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$24.01K +122.3%—1.7%
OSTXOS Therapies IncorporatedLTM Mar 2026-$1.4M -1089.2%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.94M -102.0%—581.4%
SPRBSpruce Biosciences, Inc.LTM Mar 2026-$3.18M -224.4%——
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-$7.35M -12.1%—320.6%
Peer median (excluding EQ) $24.01K-12.1%+24.9%285.8%

Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue015.76M36.08M41.1M0
Cost of Revenue0000116K
Gross Profit015.76M36.08M41.1M(116K)
Gross Margin—100.0%100.0%100.0%—
Research & Development26.38M37.55M37.04M37.43M12.84M
Selling, General & Admin11.41M17.24M13.57M11.94M10.79M
Operating Expenses37.79M77.84M50.61M49.36M23.63M
Depreciation & Amortization72K118K126K137K116K
EBITDA(37.91M)(61.26M)(12.14M)(7.57M)(22.28M)
EBITDA Margin—-388.7%-33.6%-18.4%—
Operating Income(37.79M)(62.08M)(14.52M)(8.27M)(23.63M)
Operating Margin—-393.9%-40.2%-20.1%—
Interest Income57K420K2.33M1.38M833K
Interest Expense1.07M1.05M491K00
Other Income / Expenses(1.27M)(352K)1.77M563K1.24M
Income Before Tax(39.05M)(62.43M)(12.76M)(7.71M)(22.4M)
Pre-Tax Margin—-396.1%-35.3%-18.8%—
Income Tax Expense00580K361K0
Net Income(38.98M)(62.43M)(13.34M)(8.07M)(22.4M)
Net Margin—-396.1%-37.0%-19.6%—
EPS (Basic)(1.35)(3.19)(0.38)(0.23)(0.39)
EPS (Diluted)(1.35)(3.19)(0.38)(0.23)(0.39)
Weighted Avg Shares28.81M33.73M34.73M35.36M91.88M
Weighted Avg Shares (Diluted)28.81M33.73M34.73M35.36M91.88M

Equillium, Inc.

NASDAQ:EQ

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.